Menu
Search
|

Menu

Close
X

AveXis Inc AVXS.OQ (NASDAQ Stock Exchange Global Select Market)

113.47 USD
-- (--)
As of Feb 20
chart
Previous Close 113.47
Open --
Volume --
3m Avg Volume 176,240
Today’s High --
Today’s Low --
52 Week High 127.15
52 Week Low 53.94
Shares Outstanding (mil) 35.89
Market Capitalization (mil) 4,072.89
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.83 Mean rating from 18 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-4.662
FY16
-3.713
FY15
-3.066
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
35.64
Price to Sales (TTM)
vs sector
--
8.67
Price to Book (MRQ)
vs sector
8.98
5.21
Price to Cash Flow (TTM)
vs sector
--
26.03
Total Debt to Equity (MRQ)
vs sector
0.00
15.38
LT Debt to Equity (MRQ)
vs sector
0.00
12.01
Return on Investment (TTM)
vs sector
-48.16
13.57
Return on Equity (TTM)
vs sector
-48.20
15.19

EXECUTIVE LEADERSHIP

Daniel Welch
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Sean Nolan
President, Chief Executive Officer, Director, Since 2015
Salary: $448,462.00
Bonus: --
Phillip Donenberg
Principal Financial Officer, Senior Vice President, Principal Accounting Officer, Since 2017
Salary: --
Bonus: --
Lori Smith
Chief Human Resource Officer, Senior Vice President, Since 2017
Salary: --
Bonus: --
Michael Johannesen
Senior Vice President, Chief Compliance Officer, General Counsel, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

2275 Half Day Rd Ste 160
BANNOCKBURN   IL   60015-1221

Phone: +1972.7257797

AveXis, Inc. is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company's product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration. The survival motor neuron (SMN) is a protein for normal motor neuron signaling and function. Patients with SMA Type 1 either have experienced a deletion of their SMN1 genes, which prevents them from producing adequate levels of functional SMN protein, or carry a mutation in their SMN1 gene. AVXS-101 is designed to deliver a functional human SMN gene into the nuclei of motor neurons that then generates an increase in SMN protein levels.

SPONSORED STORIES